Compare RAND & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAND | LTRN |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 27.6M |
| IPO Year | 1996 | 2020 |
| Metric | RAND | LTRN |
|---|---|---|
| Price | $10.02 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 1.6K | ★ 295.9K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $0.76 |
| 52 Week High | $17.49 | $4.58 |
| Indicator | RAND | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 18.63 |
| Support Level | N/A | N/A |
| Resistance Level | $10.39 | $1.96 |
| Average True Range (ATR) | 0.23 | 0.13 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 16.79 | 1.26 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.